Lifileucel

立非仑赛

Report date: 2026/05/16 20:00:17

Base Information

Drug NameLifileucel
Drug Alias NameAutologous T-cell therapy(Iovance Biotherapeutics)Autologous-tumour-infiltrating-lymphocytes(Iovance Biotherapeutics)TILs(Iovance Biotherapeutics)Tumour infiltrating lymphocytes(Iovance Biotherapeutics)Contego +[8] 
ClassificationCell and gene therapy > Cell therapy > Source of cells > Tumor-derivedCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Tumor Infiltrating LymphocytesCell and gene therapy > Cell therapy > Donor > Autologous
Mechanisms of ActionT lymphocyte replacementsImmunologic cytotoxicity
TargetsNot applicable
Therapy Area/IndicationsUveal melanomaSkin MelanomaUterine Cervical Neoplasms +[6] 
Global Approved IndicationsMelanoma
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date2024/02/16
Country/TerritoryBelgiumCanadaUnited States +[17] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesIovance Biotherapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesIovance Biotherapeutics Inc
Inactive CompaniesCase Comprehensive Cancer Center
Active IndicationsUveal melanomaSkin MelanomaUterine Cervical Neoplasms +[4] 
Inactive IndicationsCarcinoma, Non-Small-Cell LungSquamous Cell Carcinoma of Head and Neck

Other Information

ATC CodeN/A
Related LinksWikipediaDrugBankKEGG